Prostate cancer relapse after therapy with curative intention: A diagnostic and therapeutic dilemma

Onkologie

Volumn 28, Issue 6-7, 2005, Pages 361-366

  Gronau, Eckart ^a   Goppelt, Marcus ^a   Harzmann, Rolf ^a   Weckermann, Dorothea ^a  

^a KLINIKUM AUGSBURG   (Germany)

Author keywords

Prognostic factors; Prostate cancer; PSA doubling time; Relapse, biochemical

Indexed keywords

ANTIANDROGEN; BISPHOSPHONIC ACID DERIVATIVE; CAPROMAB PENDETIDE IN 111; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN; PROTEIN TYROSINE KINASE INHIBITOR;

ABDOMINAL DISCOMFORT; BIOCHEMISTRY; CANCER DIAGNOSIS; CANCER GRADING; CANCER GROWTH; CANCER INFILTRATION; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURGERY; COMORBIDITY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CRYOTHERAPY; DIAGNOSTIC IMAGING; DISEASE COURSE; DRUG HYPERSENSITIVITY; GYNECOMASTIA; HIGH INTENSITY FOCUSED ULTRASOUND; HORMONE DETERMINATION; HUMAN; KINETICS; LIFE EXPECTANCY; LYMPH NODE METASTASIS; NORTH AMERICA; NUCLEAR MAGNETIC RESONANCE IMAGING; ORCHIECTOMY; PATIENT INFORMATION; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SALVAGE THERAPY; SEMINAL VESICLE; TREATMENT INDICATION; WESTERN EUROPE;

HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 20444488799     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000085661     Document Type: Review

References (43)

1. Sakr WA, Grignon DJ, Crissman JD, Heilbrun LK, Cassin BJ, Pontes JJ, Haas GP: High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 1994;8:439-443.
2. Jemal A, Thomas A, Murray T, Thun M: Cancer statistics 2002. CA Cancer J Clin 2002;52:23-47.
3. Bartsch G, Horninger W, Klocker H, Reissigl A, Oberaigner W, Schonitzer D, Severi G, Robertson C, Boyle P; Tyrol Prostate Cancer Screening Group: Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 2001;58: 417-424.
4. Hankey BF, Feuer EJ, Clegg LX, Hayes RB, Legler JM, Prorok PC, Ries LA, Merrill RM, Kaplan RS: Cancer surveillance series: interpreting trends in prostate cancer part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 1999; 91:1017-1024.
5. Presman D: Operative technique of retropubic prostatectomy. Surgery 1952;32:732-743.
6. Jakse G, Manegold E, Reineke T, Borchers H, Brehmer B, Wolff JM, Mittermayer C: Expanded, radical perineal prostatectomy. Urologe A 2000;39: 455-462.
7. Sotelo R, Spaliviero M, Garcia-Segui A, Hasan W, Novoa J, Desai MM, Kaouk JH, Gill IS: Laparoscopic retropubic simple prostatectomy. J Urol 2005;173:757-760.
8. Nilsson S, Norlen BJ, Widmark A: A systematic overview of radiation therapy effects in prostate cancer. Acta Oncol 2004;43:316-381.
9. Colombel M, Gelet A: Principles and results of high-intensity focused ultrasound for localized prostate cancer. Prostate Cancer Prostatic Dis 2004;7:289-294.
10. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr., Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-1520.
11. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA; TAX 327 Investigators: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-1512.
12. Partin AW, Walsh PC: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1994;152:172-173.
13. Nelson JB, Lepor H: Prostate cancer: radical prostatectomy. Urol Clin North Am 2003;30: 703-723.
14. American Society for Therapeutic Radiology and Oncology Consensus Panel: Consensus statement: guidelines for PSA following radiation therapy. Int J Radial Oncol Biol Phys 1997;37:1035-1041.
15. Shipley WU, Thames HD, Sandler HM, Hanks GE, Zietman AL, Perez CA, Kuban DA, Hancock SL, Smith CD: Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA 1999;281:1598-1604.
16. Scheepe JR, Vis AN, Mickisch GH: Recurrence after radical prostatectomy for organ confined prostate cancer. Onkologie 2003;26:330-333.
17. Swindle PW, Kattan PW, Scardino PT: Markers and meaning ol primary treatment failure. Urol Clin North Am 2003;30:377-401.
18. Weißbach L, Sedlmayer F: Einschätzung des PSA-Rezidivs nach kurativer Therapie des Prostatakarzinoms. J Urol Urogynäkol 2004; Sonderheft 3:3-11.
19. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-1597.
20. Stephenson AJ, Shariat SF, Zelefsky MJ, Kattan MW, Butler EB, Teh BS, Klein EA, Kupelian PA, Roehrborn CG, Pistenmaa DA, Pacholke HD, Liauw SL, Katz MS, Leibel SA, Scardino PT, Slawin KM: Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 2004; 291:1325-1332.
21. D'Amico AV, Hanks GE: Linear regressive analysis using prostate specific antigen doubling time for prediction tumor biology and clinical outcome in prostate cancer. Cancer 1993;72:2638-2643.
22. Patel A, Dorey F, Franklin J: Recurrence patterns after radical retropubic prostatectomy: Clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol 1997; 158:1441-1445.
23. Shulman MJ, Benaim EA: The natural history of androgen independent prostate cancer. J Urol 2004;172:141-145.
24. Okotie OT, Aronson WJ, Wieder JA, Liao Y, Dorey F, DeKernion JB, Freedland SJ: Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. J Urol 2004;171:2260-2264.
25. Albertsen PC, Hanley JA, Penson DF, Fine J: Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation. J Urol 2004;171:2221-2225.
26. Kattan MW, Wheeler TM, Scardino PT: Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999;17:1499-1507.
27. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT: A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998;90: 766-771.
28. Kattan MW, Zelefsky MJ, Kupelian PA, Cho D, Scardino PT, Fuks Z, Leibel SA: Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer. J Clin Oncol 2003;21:4568-4571.
29. Kattan MW, Potters L, Blasko JC, Beyer DC, Fearn P, Cavanagh W, Leibel S, Scardino PT: Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology 2001;58:393-399.
30. Pollack A, Horwitz EM, Movsas B, Hanlon AL: Mindless or mindful? Radiation oncologists' perspectives on the evolution of prostate cancer treatment. Urol Clin North Am 2003;30:337-349.
31. Cannon GM, Walsh PC, Partin AW, Pound CR: Prostate specific antigen doubling time in the identification of patients at risk for progression after treatment and biochemical recurrence for prostate cancer. Urology 2003;62 (Suppl. 6B):2-8.
32. Sella T, Schwarte LH, Swindle PW, Onyebuchi CN, Scardino PT, Scher HI, Hricak H: Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology 2004;231:379-385.
33. Gomez P, Manoharan M, Kim SS, Soloway MS: Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: when is it indicated? BJU Int 2004;94:299-302.
34. Raj GV, Partin AW, Polascik TJ: Clinical utility of Indium 111-Capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. Cancer 2002; 94:987-996.
35. 11C-Acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl. Med 2003;44:549-555.
36. 11C-Cholin PET. J Nucl Med 2003;44:331-335.
37. 18F] fluorodeoxyglucose-positron emission tomography. J Urol 2003;169:1337-1340.
38. Bolla M, Van Poppel H, Van Cangh P, Vekemans K, Rigatti P, De Reijke T, Verbaeys A, Bosset JF, Collette L, Radiotherapy and Genito-urinary Tract Cancer Groups of the EORTC; CHR de Grenoble, Grenoble, France; UZ Gasthuisberg, Leuven, Belgium; Cliniques Universitaires St Luc, Brussels, Belgium; Virga Jesse Hospital, Hasselt, Belgium; Istituto Scientifico H.S. Raffaele, Milan, Italy; Academisch Medisch Centrum, Amsterdam, Netherlands; Universiteit Gent, Gent, Belgium; CHR de Besançon, Besançon, France; EORTC, Brussels, Belgium: Does post-operative radiotherapy (P-RXT) after radical prostatectomy (Px) improve progression-free survival (PFS) in pT3NO prostate cancer (PC)? (EORTC 22911). J Clin Oncol, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2004;22 (Suppl),:4504.
39. Huggins C, Hodges CV: Studies on prostatic cancer: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293.
40. Weckermann D, Harzmann R: Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues. Eur Urol 2004;46:279-283.
41. McLeod DG: Hormonal therapy: historical perspective to future directions. Urology 2003;61 (Suppl. 2A):3-7.
42. Formento P, Hannoun-Levi JM, Fischel JL, Magne N, Etienne-Grimaldi MC, Milano G: Dual HER 1-2 targeting of hormone-refractory prostate cancer by ZD1839 and trastuzumab. Eur J Cancer 2004;40:2837-2844.
43. Algur E, Macklis RM, Hafeli UO: Synergistic cytotoxic effects of zoledronic acid and radiation in human prostate cancer and myeloma cell lines. Int J Radiat Oncol Biol Phys 2005;61:535-542.